Attivare Therapeutics
Preclinical-stage biotechnology company developing biomaterial-based immuno-activating scaffold technology to recruit, reprogram, and release immune cells for cancer and infectious disease applications. The platform provides 3D spatiotemporal control of bioactive components and is being advanced through preclinical programs, translational work toward clinical trials, and collaborations including non-dilutive grant funding for a malaria vaccine program.
Industries
Nr. of Employees
small (1-50)
Attivare Therapeutics
Products
Biomaterial-based immunotherapy for acute myeloid leukemia (AML)
Subcutaneous biomaterial therapeutic designed to maintain remission after chemotherapy through local delivery of immunomodulators that induce differentiation and a vaccine-like immune effect (examples: GM-CSF and CpG).
Localized IL-12 biomaterial therapy for solid tumors
Biomaterial vehicle for reproducible, localized IL-12 delivery to modulate the tumor microenvironment, amplify local inflammation, and produce systemic (abscopal) immune effects.
Biomaterial-enabled malaria vaccine candidate
Vaccine approach that leverages slow, tunable release of antigen and adjuvant from a biomaterial platform to increase potency and durability of protective immune responses, aiming to reduce number of administrations.
Biomaterial-based immunotherapy for acute myeloid leukemia (AML)
Subcutaneous biomaterial therapeutic designed to maintain remission after chemotherapy through local delivery of immunomodulators that induce differentiation and a vaccine-like immune effect (examples: GM-CSF and CpG).
Localized IL-12 biomaterial therapy for solid tumors
Biomaterial vehicle for reproducible, localized IL-12 delivery to modulate the tumor microenvironment, amplify local inflammation, and produce systemic (abscopal) immune effects.
Biomaterial-enabled malaria vaccine candidate
Vaccine approach that leverages slow, tunable release of antigen and adjuvant from a biomaterial platform to increase potency and durability of protective immune responses, aiming to reduce number of administrations.
Services
Design and execution of preclinical efficacy and immunology studies to advance immunomodulatory therapeutics toward clinical evaluation.
Scale-up and cGMP manufacturing of biomaterial scaffold components to support first-in-human and early clinical trials.
Coordination of research partnerships and management of non-dilutive grant funding to advance vaccine and therapeutic programs.
Design and execution of preclinical efficacy and immunology studies to advance immunomodulatory therapeutics toward clinical evaluation.
Scale-up and cGMP manufacturing of biomaterial scaffold components to support first-in-human and early clinical trials.
Coordination of research partnerships and management of non-dilutive grant funding to advance vaccine and therapeutic programs.
Expertise Areas
- Biomaterials-based immunoengineering
- Cancer immunotherapy
- Vaccine development
- Preclinical in vivo pharmacology
Key Technologies
- Implantable/subcutaneous biomaterial scaffolds
- Controlled/sustained release systems for antigen and adjuvant
- Localized cytokine delivery
- In vivo immunomodulation platforms
News & Updates
Preclinical data for lead immunotherapy programs presented at the American Association for Cancer Research annual meeting (posters available).
Announcement of David Sherris, Ph.D. as President, CEO, and Chairman and note of progression toward clinical trials and a non-dilutive grant supporting a malaria vaccine program.
Press coverage describing licensing of biomaterials technology from an academic institute to advance immunotherapies.
Secured a $4M non-dilutive grant to support a slow-release malaria vaccine program developed in collaboration with external partners.
Poster materials for preclinical programs made available for AACR 2025.
Preclinical data for lead immunotherapy programs presented at the American Association for Cancer Research annual meeting (posters available).
Announcement of David Sherris, Ph.D. as President, CEO, and Chairman and note of progression toward clinical trials and a non-dilutive grant supporting a malaria vaccine program.
Press coverage describing licensing of biomaterials technology from an academic institute to advance immunotherapies.
Secured a $4M non-dilutive grant to support a slow-release malaria vaccine program developed in collaboration with external partners.
Poster materials for preclinical programs made available for AACR 2025.